Results 11 to 20 of about 3,932,956 (396)

SjAPI, the first functionally characterized Ascaris-type protease inhibitor from animal venoms. [PDF]

PLoS ONE, 2013
Serine protease inhibitors act as modulators of serine proteases, playing important roles in protecting animal toxin peptides from degradation. However, all known serine protease inhibitors discovered thus far from animal venom belong to the Kunitz-type ...
Zongyun Chen, Bin Wang, Jun Hu, Weishan Yang, Zhijian Cao, Renxi Zhuo, Wenxin Li, Yingliang Wu   +7 more
doaj   +1 more source

Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach

Journal of Biomolecular Structure and Dynamics, 2020
SARS-CoV-2 virus which caused the global pandemic the Coronavirus Disease- 2019 (COVID-2019) has infected about 1,203,959 patients and brought forth death rate about 64,788 among 206 countries as mentioned by WHO in the month of April 2020.
Sukanth Kumar Enmozhi, K. Raja, Irudhayasamy Sebastine, Jerrine Joseph   +3 more
semanticscholar   +1 more source

Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses

Journal of the American Chemical Society, 2022
Drugs targeting SARS-CoV-2 could have saved millions of lives during the COVID-19 pandemic, and it is now crucial to develop inhibitors of coronavirus replication in preparation for future outbreaks.
Andreas Luttens, H. Gullberg, E. Abdurakhmanov, D. D. Vo, Dario Akaberi, V. O. Talibov, N. Nekhotiaeva, L. Vangeel, S. de Jonghe, D. Jochmans, Janina Krambrich, A. Tas, Bo Lundgren, Ylva Gravenfors, Alexander J. Craig, Yoseph Atilaw, A. Sandström, Lindon W K Moodie, Å. Lundkvist, M. V. van Hemert, J. Neyts, J. Lennerstrand, J. Kihlberg, Kristian Sandberg, U. Danielson, Jens Carlsson   +25 more
semanticscholar   +1 more source

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

Science, 2020
Targeting a key enzyme in SARS-CoV-2 Scientists across the world are working to understand severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19). Zhang et al.
Linlin Zhang, Daizong Lin, Xinyuanyuan Sun, U. Curth, C. Drosten, Lucie Sauerhering, S. Becker, K. Rox, R. Hilgenfeld   +8 more
semanticscholar   +1 more source

Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors.

PLoS ONE, 2020
BackgroundChoice of initial antiretroviral therapy regimen may help children with HIV maintain optimal, continuous therapy. We assessed treatment-naïve children for differences in time to treatment disruption across randomly-assigned protease inhibitor ...
Dwight E Yin, Christina Ludema, Stephen R Cole, Carol E Golin, William C Miller, Meredith G Warshaw, Ross E McKinney, PENPACT-1 (PENTA 9 / PACTG 390) Study Team   +7 more
doaj   +1 more source

Mastering the canonical loop of serine protease inhibitors: enhancing potency by optimising the internal hydrogen bond network. [PDF]

PLoS ONE, 2011
BACKGROUND: Canonical serine protease inhibitors commonly bind to their targets through a rigid loop stabilised by an internal hydrogen bond network and disulfide bond(s).
Joakim E Swedberg, Simon J de Veer, Kei C Sit, Cyril F Reboul, Ashley M Buckle, Jonathan M Harris   +5 more
doaj   +1 more source

Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture

Cell Reports, 2021
Summary: Effective control of COVID-19 requires antivirals directed against SARS-CoV-2. We assessed 10 hepatitis C virus (HCV) protease-inhibitor drugs as potential SARS-CoV-2 antivirals. There is a striking structural similarity of the substrate binding
Khushboo Bafna, Kris White, Balasubramanian Harish, Romel Rosales, Theresa A. Ramelot, Thomas B. Acton, Elena Moreno, Thomas Kehrer, Lisa Miorin, Catherine A. Royer, Adolfo García-Sastre, Robert M. Krug, Gaetano T. Montelione   +12 more
doaj   +1 more source

Structural determinants for subnanomolar inhibition of the secreted aspartic protease Sapp1p from Candida parapsilosis

Journal of Enzyme Inhibition and Medicinal Chemistry, 2021
Pathogenic Candida albicans yeasts frequently cause infections in hospitals. Antifungal drugs lose effectiveness due to other Candida species and resistance. New medications are thus required. Secreted aspartic protease of C.
Jiří Dostál, Jiří Brynda, Lucie Vaňková, Syeda Rehana Zia, Iva Pichová, Olga Heidingsfeld, Martin Lepšík   +6 more
doaj   +1 more source

Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1 [PDF]

, 2005
Increased susceptibility to the protease inhibitors saquinavir and amprenavir has been observed in human immunodeficiency virus type 1 (HIV-1) with specific mutations in protease (V82T and N88S).
Clotet, B, Frost, SDW, Leigh Brown, AJ, Martinez-Picado, J, Parkin, NT, Petropoulos, CJ, Ruiz, L, Wrin, T   +7 more
core   +2 more sources

HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat

Retrovirology, 2011
Background Maturation inhibitors are an experimental class of antiretrovirals that inhibit Human Immunodeficiency Virus (HIV) particle maturation, the structural rearrangement required to form infectious virus particles.
Konvalinka Jan, Maas Renée EM, Schipper Pauline J, Pokorná Jana, van Maarseveen Noortje M, Fun Axel, Nijhuis Monique   +6 more
doaj   +1 more source